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Abstract: New Schiff bases have been prepared by reacting 3-hydroxy-4-pyridine-
carboxaldehyde with various amines. NMR spectroscopic methods provided clear 
evidence that the Schiff bases exist in the solid state and in solution as hydroxyimino 
tautomers with the E-configuration. A study of the stabilities of the tautomeric forms and 
the different conformers has been carried out using density functional calculations at the 
B3LYP/6-31G** level. 
Keywords: Schiff bases, Tautomerism, Hydrogen bonds, NMR spectroscopy, Density 
functional calculations. 
 
Introduction 
It is well established that hydrogen bonds (HB) and proton transfer (PT) reactions play a crucial 
role in many areas of physical, chemical and biological phenomena. It appears that the low-barrier 
hydrogen bond (LBHB) may act by stabilizing intermediates in enzymatic reactions and lowering the 
energy of transition states [1]. Schiff bases derived from o-hydroxyarylaldehydes have attracted much 
attention because of the tautomeric equilibria between their hydroxyimino and oxoenamino forms, as 
shown in Scheme 1 [2-7], their ability to act as ligands with many different metals in various oxidation 
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states, to the point of being considered “privileged ligands” [8], and also due to their biological 
properties [9,10].  
Scheme 1 
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Within the framework of a general project investigating mechanisms of enzymatic reactions 
involving hydroxypyridines [11], we have already studied the new Schiff bases 5a-5f and 6a-6d shown 
in Scheme 2, obtained from 3-hydroxy-4-pyridinecarboxaldehyde (1), and 4-R-substituted anilines 2a-
2f or N-aminoazoles 3a-3d, including their preparation and structural studies in solution (1H-, 13C- and 
15N-NMR spectroscopy) and in solid state (13C- and 15N-CPMAS NMR) [6,12]. As an extension of 
that work, we now present our results concerning derivatives 7a-7e, obtained from 1 and the 
corresponding N-aminobenzazoles 4a-4e. 
 
Results and Discussion 
Like the previously reported reactions of 3-hydroxy-4-pyridinecarboxaldehyde (1) with the amines 
2a-2f and 3a-3d to give the series of compounds 5 and 6, reaction of 1 with 4a-4e afforded the imines 
7a-e in nearly quantitative yields (Scheme 2). 
 
Scheme 2 
 
 
 
 
 
 
 
 
 
 
The relative stabilities of the hydroxyimino/oxoenamino tautomers have also been approached 
using B3LYP/6-31G** calculations; in the case of compound 7a the hydroxyimino tautomer with E 
configuration is more stable than the oxoenamino one by about 48.3 kJ mol–1. The presence of a N 
HC NN R
OH
N N
N
N
N
N
N
N
N N
N
CHO
OH
H2N R
H CH3 OCH3 Br Cl NO2
N
N
N
N
N
N
N
N
N
N
N
N
+
Toluene / ∆
a b c d
1 5, 6, 72, 3, 4
2
a b c d
3
4
e f
a b c d e
2
3
4
56
1
1'
2'
3' 3'a 4'
5'
6'
7'7'a 1' 1' 1' 1'
2'
2' 2' 2'
3' 3' 3' 3'3'a 3'a 3'a 3'a
7'a 7'a 7'a 7'a
7' 7' 7' 7'
6' 6' 6' 6'
5' 5' 5' 5'
4' 4' 4' 4'
Prod.R-NH2
5
6
7
Molecules 2006, 11 
 
455
atom in the α position, as in compounds 7b-7e, further increases the stability difference to the point 
that only the hydroxyimino tautomer is at an energy minimum. In all cases only the E isomer has been 
observed, as proven by 2D-NOESY NMR experiments showing the correlation between the imino 
proton and the pyridine H5 proton (Scheme 3). These results are in full agreement with the B3LYP/6-
31G** calculations, which favor the E isomer over the Z isomer by 52.4 kJ mol–1 in compound 7a, 
49.0 kJ mol–1 in 7b, 45.3 kJ mol–1 in 7c, 50.0 kJ mol–1 in 7d and 56.3 kJ mol–1 in 7e, respectively. 
 
Scheme 3 
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These results are in agreement with the experimental NMR observations. The signals providing 
more information on the type of tautomer are those corresponding to the CH=N atom, with 15N-NMR 
chemical shifts between –63.8 ppm and –90.2 ppm in DMSO-d6. These values are typical of the non-
protonated nitrogen atom of a Schiff base and indicate that compounds 7a-7e exist in the 
hydroxyimino tautomeric form. 
The OH group can form either an intramolecular hydrogen bond with the imino nitrogen, as in 
conformations A and B, or intermolecular hydrogen bonds. The latter structures can in turn present 
several different conformations (C-F) by rotation around the N-N and C-C bonds (Figure 1 and Figure 
2).  
 
Figure 1. Calculated conformations A-F for (E)-4-[1H-benzazol-1-ylimino)methyl]-
pyridin-3-ols (7a, X=CH, Y=N; 7b, X=N, Y=CH; 7d, X=Y=N). 
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Figure 2.  Calculated conformations A-F for (E)-4-[(2H-benzazol-2-ylimino)methyl]-
pyridine-3-ols (7c, X=N, Y=CH; 7e, X=Y=N). 
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The B3LYP/6-31G** calculated energies of the different conformers are summarized in Table 1, 
where it is seen that the most stable form is the A one, with an intramolecular hydrogen bond and the 
azole part of the benzazole moiety directed towards the same side of the imino proton. 
 
Table 1. Absolute energies (in hartrees) and relative energies (in kJ mol–1) of structures A-F. 
 
In 7a the two conformers with intramolecular hydrogen bond (A and B) are of similar energy and 
the existence of both in CDCl3 has been experimentally observed by means of a NOESY spectrum 
showing the correlations existing between the imino proton and H2’ and H7’ of the benzimidazole ring 
(Figure 3). 
Figure 3. NOESY spectrum of compound 7a in CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
Compound  A B C D E F 
7a  
+ZPE 
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7b  
+ZPE 
-795.6071 (0.0) 
-795.3931 (0.0) 
29.1 
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7c  
+ZPE 
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26.0 
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7d  
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The NOESY spectrum of derivative 7b in CDCl3 also demonstrates that it exists in the most stable 
form A, with the OH forming an intramolecular hydrogen bond with the imino N atom (Figure 4). 
 
Figure 4. NOESY spectrum of compound 7b in CDCl3. 
 
 
 
 
 
  
 
 
 
 
 
 
In DMSO-d6 solution, where the intramolecular hydrogen bonds are disrupted, the observed 
conformation is the E form, as theoretical calculations predict and NOESY experiments have 
confirmed (Figure 5). 
 
Figure 5. NOESY spectrum of compound 7b in DMSO-d6 
 
 
 
 
 
 
 
 
 
 
 
 
For all compounds 7a-7e, the complete assignment of the 1H-, 13C- and 15 N-NMR signals in 
CDCl3 and DMSO-d6 has been achieved taking into account the chemical shift values, their 
multiplicity, as well as homonuclear (COSY and NOESY) and heteronuclear (HMQC and HMBC) 
correlations [13]. The values are given in the Experimental section. 
In addition to what was stated previously, the most relevant NMR data for our study have been: i) 
in 1H-NMR, the chemical shifts of the imino proton CH=N with mean values of 9.40 ppm in CDCl3 
and 9.60 ppm in DMSO-d6, while the OH proton is around 10.2 ppm in CDCl3 and 10.93 ppm in 
DMSO-d6; ii) in 13C-NMR, the imino carbon CH=N at around 152.5 ppm in CDCl3 and at around 
147.2 ppm in DMSO-d6; iii) in 15N-NMR, the imino nitrogen CH=N in the range of –63.8 to –90.2 
ppm and the pyridine N atom at about -51 ppm in DMSO-d6. 
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Finally, 13C- and 15N-CPMAS NMR studies have also been performed for all five derivatives 7a-
7e, demonstrating that in solid state there is no intramolecular hydrogen bond and that they exist 
predominantly as E rotamers. Two beautiful 13C-NMR spectra of 7b and 7e are shown in Figure 6, 
where the upper part presents only the quaternary carbon atoms (NQS spectra) and the lower part 
presents the full spectrum. 
 
Figure 6. 13C-CPMAS NMR spectra of compounds 7b and 7e. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Compound 7b                Compound 7e 
 
The splitting observed in some signals could be explained as due to the presence of more than one 
rotamer or to the different disposition of a same isomer in the solid state. 
 
Conclusions 
All Schiff bases studied show a similar behavior, existing as the corresponding E-isomers in the 
hydroxyimino tautomeric form in solution and in the solid state. An overview of the 1H-NMR, 13C- 
NMR and 15N-NMR chemical shifts (δ in ppm) is shown in Scheme 3. 
Scheme 3.  
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Experimental 
General  
Melting points were determined both under an Axiolab "Zeiss" microscope with a TMS 92 
LINKAN heating stage and by DSC on a SEIKO DSC 220C connected to a Model SSC5200H Disk 
Station. Thermograms (sample size 0.003-0.010 g) were recorded at the scanning rate of 2.0 ºC min-1. 
Unless otherwise stated, column chromatography was performed on silica gel (Merck 60, 70-230 
mesh). The Rf values were measured on aluminium backed TLC plates of silica gel 60 F254 (Merck, 
0.2 mm) with the indicated eluent. Elemental analyses were performed using Perkin-Elmer 240 by 
“Centro de Microanálisis Elemental-UCM, Madrid”. 
 
NMR spectroscopy [13] 
 
Solution NMR spectra were recorded on a Bruker DRX 400 spectrometer (9.4 Tesla, 400.13 MHz 
for 1H-, 100.62 MHz for 13C- and 40.56 MHz for 15N-) with a 5-mm inverse-detection H-X probe 
equipped with a z-gradient coil, at 300 K. Chemical shifts (δ in ppm) are given from internal solvent, 
CDCl3 7.26 for 1H- and 77.0 for 13C-, DMSO-d6 2.49 for 1H- and 39.5 for 13C- and for 15N-NMR 
nitromethane (0.00) was used as external standard. Typical parameters for 1H-NMR spectra were 
spectral width 4000 Hz and pulse width 7.5 µs at an attenuation level of 0 dB and resolution 0.15-0.25 
Hz per point. Typical parameters for 13C-NMR spectra were as follows: spectral width 21 kHz, pulse 
width 10.6 µs at an attenuation level of -6 dB, resolution 0.6 Hz per point and relaxation delay 2 s; 
WALTZ-16 was used for broadband proton decoupling; the FIDS were multiplied by an exponential 
weighting (lb = 2 Hz) before Fourier transformation. 2D (1H-1H) gs-COSY and inverse proton detected 
heteronuclear shift correlation spectra, (1H-13C) gs-HMQC, (1H-13C) gs-HMBC and (1H-15N) gs-
HMBC, were acquired and processed using standard Bruker NMR software and in non-phase-sensitive 
mode. Gradient selection was achieved through a 5% sine truncated shaped pulse gradient of 1 ms. 
Selected parameters for (1H-1H) gs-COSY were spectral width 2500-3500 Hz, the acquisition data size 
was 1024 points and one transient was accumulated per increment, with a 1 s relaxation delay, for a 
total of 256 experiments, data processing using zero filling in the F1 domain and shifted sine-bell 
apodization of factor 0 in both dimensions. Selected parameters for (1H-1H) gs-NOESY were spectral 
width 2000-3000 Hz, the acquisition data size was 1024 points and 32-64 transient was accumulated 
per increment, with a 1 s relaxation delay, 1000-2000 ms for the mixing time, for a total of 512 
experiments, data processing using zero filling in the F1 domain and shifted sine-bell apodization of 
factor 0 in both dimensions. Selected parameters for (1H-13C) gs-HMQC and gs-HMBC spectra were 
spectral width 2500-3500 Hz for 1H and 12.0-20.5 kHz for 13C, 1024 x 256 data set, number of scans 2 
(gs-HMQC) or 4 (gs-HMBC) and relaxation delay 1s. The FIDs were processed using zero filling in 
the F1 domain and a sine-bell window function in both dimensions was applied prior to Fourier 
transformation. In the gs-HMQC experiments GARP modulation of 13C was used for decoupling. 
Selected parameters for (1H-15N) gs-HMBC spectra were spectral width 2500-3500 Hz for 1H and 12.5 
kHz for 15N, 1024 x 256 data set, number of scans 4, relaxation delay 1s, 50-75 ms delay for the 
evolution of the 15N-1H long-range coupling. The FIDs were processed using zero filling in the F1 
domain and a sine-bell window function in both dimensions was applied prior to Fourier 
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transformation. Solid state 13C- (100.73 MHz) and 15N- (40.60 MHz) CPMAS NMR spectra have been 
obtained on a Bruker WB 400 spectrometer at 300 K using a 4 mm DVT probehead. Samples were 
carefully packed in a 4-mm diameter cylindrical zirconia rotor with Kel-F end-caps. Operating 
conditions involved 3.2 µs 90° 1H pulses and decoupling field strength of 78.1 kHz by TPPM 
sequence. 13C-NMR spectra were originally referenced to a glycine sample and then the chemical 
shifts were recalculated to the Me4Si [for the carbonyl atom δ(glycine) = 176.1 ppm] and 15N- spectra 
to 15NH4Cl and then converted to nitromethane scale using the relationship: δ 15Ν (ΜεΝΟ2) = δ 
15N(NH4Cl) – 338.1 ppm. Typical acquisition parameters for 13C-CPMAS were: spectral width, 40 
kHz; recycle delay, 5-120 s; acquisition time, 30 ms; contact time, 2-6 ms; and spin rate, 12 kHz. In 
order to distinguish protonated and unprotonated carbon atoms, the NQS (Non-Quaternary 
Suppression) experiment by conventional cross-polarization was recorded; before the acquisition the 
decoupler is switched off for a very short time of 25 µs [14-16]. Typical acquisition parameters for 15N 
CPMAS were: spectral width, 40 kHz; recycle delay, 5-120 s; acquisition time, 35 ms; contact time, 5-
8 ms; and spin rate, 6 kHz. 
 
DFT calculations 
 
The optimization of the structures of all compounds discussed in this paper was carried out at the 
hybrid B3LYP/6-31G** level [17-21] with basis sets of Gaussian type functions using Spartan ’02 for 
Windows [22]. 
 
Synthesis of compounds 7a-7e  
 
The compounds were prepared in nearly quantitative yields (85-90%) by refluxing equimolar 
amounts of 1 [6] and the corresponding amines 4a-4e [23] in toluene during 7 h and then stirring 
overnight. 
 
4-[(E)-(1H-benzimidazol-1-ylimino)methyl]pyridin-3-ol (7a). TLC [Rf 0.44 (9:1 CHCl3-C2H5OH)]. The 
crystals were purified by crystallisation (from C2H5OH), mp 239 ºC (microscope) and 239.1 ºC with 
decomposition at 255.5 (DSC); Anal. Calcd for C13H10N4O: C, 65.54; H, 4.23; N, 23.52. Found: C, 
64.48; H, 4.33; N, 23.42; 1H-NMR (DMSO-d6) δ: 10.80 (s vbr, 1H, OH), 9.29 (s, 1H, CH=N), 9.07 (s, 
1H, C2’-H), 8.38 (s br, 1H, C2-H), 8.18 (d br, 1H, 3J5-6= 4.8, C6-H), 7.84 (d, 1H, C5-H), 7.79 (d, 1H, 
3J6’-7’= 8.0, C7’-H), 7.72 (d, 1H, 3J5’-4’= 7.9, C4’-H4), 7.40 (t, 1H, C6’-H), 7.31 (t, 1H, C5’-H); 13C-NMR 
(DMSO-d6) δ: 152.6 (C3), 146.9 (CH=N, 1J=169.6), 141.8 (C3’a), 140.5 (C6, 1J=181.2, 3J=11.9), 139.9 
(C2, 1J=179.2, 3J=11.3), 137.0 (C2’, 1J=214.0), 132.1 (C7’a), 125.6 (C4), 124.0 (C6’, 1J=161.0, 3J=7.8), 
123.0 (C5’, 1J=160.4, 3J=7.8), 120.1 (C4’, 1J=161.8, 3J=8.0), 119.4 (C5, 1J=161.9), 110.7 (C7’, 1J=165.0, 
3J=8.3); 15N-NMR (DMSO-d6) δ: -181.2 (N1’), -134.4 (N3’), -70.3 (CH=N), -53.2 (N1); 1H-NMR 
(CDCl3) δ: 10.20 (s br, 1H, OH), 8.90 (s, 1H, CH=N), 8.58 (s br, 1H, C2-H), 8.41 (s, 1H, C2’-H),  8.34 
(d , 1H, 3J5-6= 5.0, C6-H), 7.86 (ddd, 1H, 3J5’-4’= 8.0, 4J6’-4’= 1.3, 5J7’-4’= 0.7, C4’-H), 7.69 (ddd, 1H, 3J6’-
7’= 7.9,  3J5’-7’= 1.3, C7’-H), 7.46 (ddd, 1H, C6’-H), 7.41 (ddd, 1H, C5’-H), 7.31 (d, 1H, C5-H); 13C-NMR 
(CDCl3) δ: 152.9 (C3), 152.1 (CH=N), 142.6 (C3’a), 141.4 (C6), 141.3 (C2), 135.9 (C2’), 131.0 (C7’a), 
125.1 (C6’), 124.2 (C5’), 123.5 (C5), 121.9 (C4), 121.4 (C4’,), 110.2 (C7’); 15N-NMR (CDCl3) δ:-186.5 
(N1’); 13C-CP/MAS NMR  δ: 154.0 (C3), 140.7 (CH=N), 140.7 (C3’a), 140.1 (C6), 138.2 (C2), 137.3 
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(C2’), 133.7 (C7’a), 128.1 (C4), 122.8 (C6’), 122.0 (C5’), 119.1 (C4’), 118.6 (C5), 113.0 (C7’); 15N- 
CP/MAS NMR  δ: -177.7 (N1’), -135.1 (N3’), -87.1 (CH=N), -67.6 (N1). 
 
4-[(E)-(1H-indazol-1-ylimino)methyl]pyridin-3-ol (7b). TLC [Rf 0.82 (9:1 CHCl3-C2H5OH)]. The 
crystals were purified by crystallisation (from CHCl3-C2H5OH), mp 190 ºC (microscope) and 186.0 ºC 
(DSC); Anal. Calcd for C13H10N4O: C, 65.54; H, 4.23; N, 23.52. Found: C, 63.25; H, 4.24; N, 22.76; 
1H-NMR (DMSO-d6) δ: 10.69 (s br, 1H, OH), 9.37 (s, 1H, CH=N), 8.35 (s, 1H, C2-H), 8.34 (t, 1H, 
4J4’-3’=5J7’-3’=0.8, C3’-H), 8.16 (d, 1H, 3J5-6= 5.0, C6-H), 7.89 (d, 1H, C5-H), 7.87 (ddd, 1H, 3J6’-7’= 8.1, 
4J5’-7’= 0.9, C7’-H), 7.84 (ddd, 1H, 3J5’-4’=8.0, 4J6’-4’= 1.0, C4’-H), 7.56 (ddd,  1H, 3J5’-6’= 6.9, C6´-H), 
7.29 (ddd,  H5’); 13C-NMR (DMSO-d6) δ: 152.4 (C3), 140.5 (C6, 1J=181.6, 3J=11.1), 139.8 (CH=N, 
1J=172.0), 139.6 (C2, 1J=178.5, 3J=11.3), 137.6 (C7’a, 3J=3J=9.1), 134.2 (C3’, 1J=192.8), 128.3 (C6’, 
1J=159.6, 3J=7.7, 2J=2.2), 125.8 (C4), 123.5 (C3’a), 122.6 (C5’, 1J=161.3, 3J=7.0), 121.5 (C4’, 1J=163.8, 
3J=8.2), 118.9 (C5, 1J=163.9, 3J=9.8, 2J=4.1), 110.0 (C7’, 1J=167.5, 3J=8.4); 15N-NMR (DMSO-d6) δ: -
157.5 (N1’), -81.8 (N2’), -70.1 (CH=N), -54.4 (N1); 1H-NMR (CDCl3) δ: 10.37 (s, 1H, OH), 9.18 (s, 
1H, CH=N), 8.51 (s, 1H, C2-H), 8.28 (d, 1H, 3J5-6= 4.9, C6-H), 8.11 (t, 1H, 4J4’-3’=5J7’-3’=0.9, C3’-H), 
7.75 (td, 1H, 3J5’-4’=8.1, 4J6’-4’= 0.9, C4’-H), 7.70 (qd, 1H, 3J6’-7’= 8.4, 4J5’-7’= 0.9, C7’-H), 7.55 (ddd,  
1H, 3J5’-6’= 7.0, C6´-H), 7.29 (d, 1H, C5-H), 7.29 (ddd,  H5’); 13C-NMR (CDCl3) δ: 152.6 (C3), 141.2 
(C6, 1J=181.2, 3J=11.5), 146.2 (CH=N, 1J=172.4, 3J=6.3), 140.6 (C2, 1J=181.1), 137.5 (C7’a), 134.6 
(C3’, 1J=191.4, 3J=2.5), 128.7 (C6’, 1J=161.0, 3J=7.7), 123.6 (C5, 1J=158.0), 123.1 (C5’, 1J=162.6), 
122.9 (C4), 124.0 (C3’a), 121.5 (C4’, 1J=163.5, 3J=8.1), 109.5 (C7’, 1J=167.3, 3J=7.9); 15N-NMR 
(CDCl3) δ: -162.8 (N1’), -86.2 (N2’), -83.9 (CH=N), -59.7 (N1); 13C-CP/MAS NMR  δ: 155.6/153.8 
(C3), 137.9 (C7’a), 137.5 (C6 and CH=N), 135.9 (C2), 134.5 (C3’), 130.3 (C6’), 128.9 (C4), 123.9/122.4 
(C3’a), 121 (C5’ and C4’), 119.1 (C5), 109.4 (C7’); 15N- CP/MAS NMR  δ: -154.5 (N1’), -88.7 (N2’), -
80.8 (CH=N), -68.9 (N1).  
 
4-[(E)-(2H-indazol-2-ylimino)methyl]pyridin-3-ol (7c). TLC [Rf 0.79 (9:1 CHCl3-C2H5OH)]. The 
crystals were purified by crystallisation (from C2H5OH), mp 270 ºC (microscope) and 267.7 ºC with 
decomposition at 284.7 (DSC); Anal. Calcd for C13H10N4O: C, 65.54; H, 4.23; N, 23.52. Found: C, 
64.75; H, 4.39; N, 23.30; 1H-NMR (DMSO-d6) δ: 10.94 (s, 1H, OH), 9.77 (s, 1H, CH=N), 8.70 (d, 1H, 
5J7’-3’=0.9, C3’-H), 8.40 (s, 1H, C2-H), 8.20 (d, 1H, 3J5-6=5.0, C6-H), 7.81 (d, 1H, C5-H), 7.75 (td, 1H,  
3J5’-4’=8.5, 4J6’-4’=5J7’-4’=1.1, C4’-H), 7.66 (qd, 1H, 3J6’-7’=8.8, 4J5’-7’=1.0, C7’-H), 7.36 (ddd, 1H, 3J5’-
6’=6.6, C6’-H), 7.11 (ddd, 1H, C5’-H); 13C-NMR (DMSO-d6) δ: 153.8 (C3), 148.9 (CH=N, 1J=176.1), 
146.0 (C7’a, 3J=3J=3J=7.3), 140.5 (C6, 1J=180.7, 3J=11.7), 140.2 (C2, 1J=179.8, 3J=11.1), 127.9 (C6’, 
1J=158.5, 3J=7.3), 124.4 (C4), 123.7 (C3’, 1J=197.1), 122.2 (C5’, 1J=159.9, 3J=8.2), 121.3 (C3’a), 121.2 
(C4’, 1J=163.9, 3J=7.4), 119.5 (C5, 1J=164.5, 3J=8.5), 117.2 (C7’, 1J=163.1, 3J=7.0); 15N-NMR (DMSO-
d6) δ: -125.5 (N2’), -63.8 (CH=N), -50.5 (N1); 1H-NMR (CDCl3) δ: 10.14 (s, 1H, OH), 9.61 (s, 1H, 
CH=N), 8.56 (s, 1H, C2-H), 8.23 (d, 1H, 5J7’-3’=0.9, C3’-H), 8.33 (d, 1H, 3J5-6=4.9, C6-H), 7.69 (m, 2H,  
C4’-H and C7’-H), 7.39 (ddd, 1H, 3J5’-6’=6.6 3J7’-6’=8.9, 5J4’-6’=1.0, C6’-H), 7.37 (d, 1H, C5-H), 7.15 
(ddd, 1H, 3J4’-5’=8.4, 4J7’-5’=0.8, C5’-H); 13C-NMR (CDCl3) δ: 154.5 (CH=N), 153.0 (C3), 147.0 (C7’a), 
141.6 (C6), 141.2 (C2), 128.6 (C6’), 124.5 (C5), 123.1 (C5’), 122.5 (C3’), 121.8 (C3’a), 121.7 (C4), 120.7 
(C4’), 117.5 (C7’); 15N-NMR (CDCl3) δ: -133 (N2’); 13C-CP/MAS NMR δ: 156.1 (C3), 146.9 (CH=N), 
145.0 (C7’a), 141.3 (C6), 139.4 (C2), 129.3 (C4), 127.4 (C6’), 123.5 (C3’), 121.7 (C5’ and C3’a), 121.1 
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(C4’), 119.6 (C5), 118.4 (C7’); 15N-CP/MAS NMR δ: -122.9 (N2’),  -110.6 (N1’), -84.0 (CH=N),  -69.9/-
66.7 (N1). 
 
4-[(E)-(1H-1,2,3-benzotriazol-1-ylimino)methyl]pyridin-3-ol (7d). TLC [Rf 0.70 (9:1 CHCl3-
C2H5OH)]. The crystals were purified by crystallisation (CHCl3), mp 209 ºC (microscope) and 199.9 
ºC and 204.7 ºC with decomposition at 237.1 ºC (DSC); Anal. Calcd for C12H9N5O: C, 60.25; H, 3.79; 
N, 29.27. Found: C, 60.01; H, 4.28; N, 28.12; 1H-NMR (DMSO-d6) δ: 11.00 (s br, 1H, OH), 9.75 (s, 
1H, CH=N), 8.41 (s, 1H, C2-H), 8.22 (d, 1H, 3J5-6=5.0, H6), 8.13 (td, 1H, 3J5’-4’=8.4, 4J6’-4’=5J7’-4’=1.0, 
C4’-H), 7.96 (td,1H, 3J6’-7’=8.3, 4J5’-7’=1.0, C7’-H) 7.93 (d, 1H, C5-H), 7.70 (ddd, 1H, 3J5’-6’=6.9, C6’-H), 
7.51 (ddd, 1H, C5’-H); 13C-NMR (DMSO-d6) δ: 153.1 (C3), 147.2 (CH=N, 1J=173.4), 144.8 (C3’a, 
3J=9.8, 3J=4.5), 140.5 (C6, 1J=181.3, 3J=11.5), 140.2 (C2, 1J=179.4, 3J=11.4), 130.4 (C7’a, 3J=10.6, 
3J=6.5), 129.2 (C6’, 1J=163.5, 3J=7.8), 125.3 (C5’, 1J=164.0, 3J=7.7), 124.6 (C4), 119.8 (C4’, 1J=166.5, 
3J=7.8), 119.2 (C5, 1J=163.2), 110.5 (C7’, 1J=168.9, 3J=8.2); 15N-NMR (DMSO-d6) δ: -121.6 (N1’), -
77.1 (CH=N), -49.7 (N1); 1H-NMR (CDCl3) δ: 10.20 (s br, 1H, OH), 9.64 (s, 1H, CH=N), 8.59 (s, 1H, 
C2-H), 8.35 (d, 1H, 3J5-6=4.6, C6-H), 8.11 (d, 1H, 3J5’-4’=8.3, C4’-H), 7.76 (d, 1H, 3J6’-7’=8.2, C7’-H), 
7.65 (t, 1H, 3J5’-6’=7.5, C6’-H), 7.49 (t, 1H, C5’-H), 7.43 (d, 1H, C5-H); 13C-NMR (CDCl3) δ: 153.2 
(C3), 152.3 (CH=N, 1J=172.8, 3J=6.1), 145.5 (C3’a), 141.1 (C6, 1J=183.0, 3J=11.8), 141.0 (C2, 
1J=181.5, 3J=11.3), 130.3 (C7’a), 129.4 (C6’, 1J=163.4, 3J=8.1), 125.4 (C5’, 1J=163.7, 3J=7.9), 123.8 
(C5, 1J=164.1, 3J=8.6), 122.4 (C4), 120.5 (C4’, 1J=166.5, 3J=7.8), 109.6 (C7’, 1J=169.5, 3J=8.3); 15N-
NMR (CDCl3) δ: -126.9 (N1’), -89.4 (CH=N), -55.8 (N1); 13C-CP/MAS NMR δ: 154.8 (C3), 145.5 
(CH=N), 143.9 (C3’a), 141.1 (C6), 138.2 (C2), 130.8 (C7’a), 128.7 (C6’), 123.6 (C5’ and C4), 118.7 (C5), 
118.0 (C4’), 109.7 (C7’); 15N-CP/MAS NMR   δ: -159.0 (N1’), -80.5 (CH=N), -67.6 (N3’), -55.3 (N1), -
17.6 (N2’). 
 
4-[(E)-(2H-1,2,3-benzotriazol-2-ylimino)methyl]pyridin-3-ol (7e). TLC [Rf 0.80 (9:1 CHCl3-
C2H5OH)]. The crystals were purified by crystallisation (CHCl3), this compound changes its 
appearance at 250°C and then at 280°C it decomposes, and 259.6 ºC (DSC); Anal. calcd for 
C12H9N5O: C, 60.25; H, 3.79; N, 29.27. Found: C, 59.90; H, 3.95; N, 28.80; 1H-NMR (DMSO-d6) δ: 
11.20 (s br, 1H, OH), 9.86 (s, 1H, CH=N), 8.43 (s, 1H, C2-H), 8.20 (d, 1H, 3J5-6=5.0, C6-H), 7.97 (m, 
2H, C4’-H and C7’-H), 7.84 (d, 1H, C5-H), 7.52 (m, 2H, C5’-H and C6’-H); 13C-NMR (DMSO- d6) δ: 
153.9 (C3, 3J=2J=5.2), 153.2 (CH=N, 1J=173.0, 3J=3.1), 142.7 (C3’a and C7’a), 140.5 (C6 and C2, 
1J=180.2, 3J=11.3), 128.0 (C5’ and C6’, 1J=162.0, 3J=8.3), 123.5 (C4, 3J=3J=2J=6.0), 119.3 (C5, 
1J=164.3, 3J=9.7, 2J=3.8), 118.1 (C4’ and C7’, 1J=169.2, 3J=5.2); 15N-NMR (DMSO- d6) δ: -90.2 
(CH=N), -47.2 (N1); 1H-NMR (CDCl3) δ: 10.02 (s vbr, 1H, OH), 9.68 (s, 1H, CH=N), 8.62 (s, 1H, C2-
H), 8.36 (d, 1H, 3J5-6=4.8, C6-H), 7.90 (m, 2H, C4’-H and C7’-H), 7.49 (m, 2H, C5’-H and C6’-H), 7.42 
(d, C5-H); 13C-NMR (CDCl3) δ: 157.5 (CH=N, 1J=169.7), 153.5 (C3), 143.6 (C3’a and C7’a), 141.8 (C2, 
1J=182.1, 3J=11.0), 141.2 (C6, 1J=182.7, 3J=11.2), 128.4 (C5’ and C6’, 1J=161.4, 3J=8.2), 124.7 (C5, 
1J=162.9), 121.0 (C4), 118.4 (C4’ and C7’, 1J=170.1, 3J=4.9); 13C-CP/MAS NMR δ: 155.2 (C3), 149.1 
(CH=N), 142.8 (C3’a and C7’a), 139.8 (C6), 135.0 (C2), 129.7(C5’), 126.2, (C6’ and C4), 123.2 (C5), 
120.3 (C4’), 113.3 (C7’); 15N-CP/MAS NMR δ: -90.6 (N1’), -88.0 (N3’), -84.5 (CH=N), -83.6 (N2’), -
60.7 (N1). 
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